Cantargia Patent Granted By The European Patent Office

STOCKHOLM--(BUSINESS WIRE)--Cantargia AB (”Cantargia”) (STO:CANTA) has obtained a granted patent from the European Patent Office concerning IL1RAP as a target molecule for antibody based therapy and diagnostic methods of several types of solid tumors. The formal grant follows the previous ”Intention to Grant”-notification communicated October 6th, 2015.

Based on EPO:s grant of the patent with number 2665749, a European protection exists until 2032 and covers Cantargia’s method to utilize IL1RAP as a target molecule for treatment and diagnostics of solid tumors. The patent comprise the treatment and diagnostics of several common forms of solid tumors such as breast cancer, colon cancer, lung cancer and malignant melanoma. The corresponding application is currently under review by authorities in e.g. USA, Japan, China and Australia. Cantargia already has a patent granted by the EPO concerning treatment of hematological forms of cancer.

”We are of course very pleased to have additional patent protection for the development of our product candidate CAN04. EPO has subsequently granted two patents giving us a solid and robust protection around our method using IL1RAP as a target molecule for the treatment of several forms of cancer”, says Göran Forsberg, CEO.

This information was brought to you by Cision http://news.cision.com